Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $264.90 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vaxxinity Inc had its IPO on 2021-11-11 under the ticker symbol VAXX.
The company operates in the Healthcare sector and Biotechnology industry. Vaxxinity Inc has a staff strength of 87 employees.
Shares of Vaxxinity Inc opened at $1.77 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.59 - $1.86, and closed at $1.6.
This is a -9.6% slip from the previous day's closing price.
A total volume of 298,315 shares were traded at the close of the day’s session.
In the last one week, shares of Vaxxinity Inc have slipped by -23.45%.
Vaxxinity Inc's Key Ratios
Vaxxinity Inc has a market cap of $264.90 million, indicating a price to book ratio of 2.9213 and a price to sales ratio of 4604.903.
In the last 12-months Vaxxinity Inc’s revenue was $-1000 with a gross profit of $-1871000 and an EBITDA of $-71711000. The EBITDA ratio measures Vaxxinity Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vaxxinity Inc’s operating margin was 0% while its return on assets stood at -41.1% with a return of equity of -94.94%.
In Q2, Vaxxinity Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57.3%.
Vaxxinity Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vaxxinity Inc’s profitability.
Vaxxinity Inc stock is trading at a EV to sales ratio of 1898.0251 and a EV to EBITDA ratio of -1.4443. Its price to sales ratio in the trailing 12-months stood at 4604.903.
Vaxxinity Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $71.37 million
- Total Liabilities
- $23.78 million
- Operating Cash Flow
- $26.61 million
- Capital Expenditure
- Dividend Payout Ratio
Vaxxinity Inc ended 2023 with $71.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $71.37 million while shareholder equity stood at $35.01 million.
Vaxxinity Inc ended 2023 with $0 in deferred long-term liabilities, $23.78 million in other current liabilities, 279000.00 in common stock, $-337101000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $37.06 million and cash and short-term investments were $55.85 million. The company’s total short-term debt was $1,392,000 while long-term debt stood at $12.34 million.
Vaxxinity Inc’s total current assets stands at $59.71 million while long-term investments were $0 and short-term investments were $18.79 million. Its net receivables were $407000.00 compared to accounts payable of $1.89 million and inventory worth $2.75 million.
In 2023, Vaxxinity Inc's operating cash flow was $26.61 million while its capital expenditure stood at $90000.
Comparatively, Vaxxinity Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vaxxinity Inc stock is currently trading at $1.6 per share. It touched a 52-week high of $4.47 and a 52-week low of $4.47. Analysts tracking the stock have a 12-month average target price of $12.5.
Its 50-day moving average was $2.36 and 200-day moving average was $2.26 The short ratio stood at 35.86 indicating a short percent outstanding of 0%.
Around 5104.8% of the company’s stock are held by insiders while 2271.9% are held by institutions.
Frequently Asked Questions About Vaxxinity Inc
Similar Industry Stocks (Biotechnology)
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer’s disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.